Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

INBIOS INTERNATIONAL

InBios International, Inc. is a biotechnology company specializing in the design, development and manufacture of immu... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Tests for Visceral Leishmaniasis Reviewed

By LabMedica International staff writers
Posted on 30 Jun 2014
The effectiveness of rapid diagnostic tests (RDTs) in diagnosing patients with visceral leishmaniasis (VL) has been reviewed by an independent expert group.

VL is caused by a parasite and results in fever, a large spleen and other health problems and diagnosis is extremely important as without treatment it can be fatal and proper treatment can result in a cure. More...


Scientists from the Cochrane Infectious Disease Group, coordinated through the editorial base in Liverpool School of Tropical Medicine (UK) found 24 studies, which contained information about five different RDTs, with a total of 4,271 participants. They describe how accurate these rapid diagnostic tests are for diagnosing VL in people who, according to their physicians, could have the disease. Only studies in which the investigators had used established methods to distinguish the people with VL from those who did not have the disease were used in the review.

One RDT, the rK39 immunochromatographic test (ICT) gave correct, positive results in 92% of the people with VL and it gave correct, negative results in 92% of the people who did not have the disease. The test worked better in India and Nepal than in East Africa. In India and Nepal, it gave correct, positive results in 97% of the people with the disease. In East Africa, it gave correct, positive results in only 85% of the people with the disease.

In 11 of the studies, the InBios rK39 ICT test (Seattle WA, USA) was used; four studies assessed the DiaMed rK39 ICT test (Cressier, Switzerland) and three evaluated other tests. There were no significant differences in diagnostic accuracy between commercial brands. A second RDT, the latex agglutination test gave correct, positive results in 64% of the people with the disease and it gave correct, negative results in 93% of the people without the disease.

Marleen Boelaert, PhD, from Institute of Tropical Medicine (Antwerp, Belgium) and the senior author of the report, said, “The best chance of a cure for VL lies in a correct diagnosis, so utilizing accurate RDTs is of paramount importance. Our review indicates that the rK39 ICT shows higher sensitivity and specificity for the diagnosis of VL in patients with febrile splenomegaly and no previous history of the disease than the latex agglutination test, but the sensitivity is notably lower in East Africa than in the Indian subcontinent. The size of the studies involving the other RDTs lack accuracy, validation, or both.” The report was published on June 20, 2014, in the journal the Cochrane Library.

Related Links:

Liverpool School of Tropical Medicine
InBios
DiaMed




New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Quality Control Material
Multichem ID-B
New
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: EvoLiver is the first test to receive FDA Breakthrough Device Designation in five years in the liver cancer surveillance space (Photo courtesy of Mursla Bio)

Patient-Friendly Blood Test to Transform Liver Cancer Surveillance

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is the fastest-growing cause of cancer-related deaths. Although clinical guidelines recommend routine surveillance for high-risk... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.